The biopharma company achieved $1 billion in revenue for the first time in its September-ended quarter. More recently, it achieved a more significant milestone when it turned prof ...

Harmony Biosciences continues to deliver strong sales and earnings growth, driven by its flagship drug WAKIX and a ...

Avadel Pharmaceuticals (NASDAQ:AVDL) announced that its drug LUMRYZ (sodium oxybate) for extended-release oral suspension has ...

On June 4, Baird increased its price target for Agenus Inc. (NASDAQ: AGEN) to $6 from $4, while maintaining a Neutral rating ...

RadNet, Inc. (NASDAQ:RDNT) has moved to strengthen its prospects on the use of artificial intelligence to enhance ultrasound ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

"This publication in Gastroenterology reinforces the scientific rigor, statistical significance and clinical impact of the inFoods IBS approach for treating patients,” said Zack Irani-Cohen, CEO of ...

The analyst supported the positive rating with Ojemda’s potential, which is a prescription medicine that treats certain brain ...

The analyst based the rating update on the recent FDA approval of Ojemda (tovorafenib) for BRAF-altered, relapsed, or ...

Arcutis' approvals, growth, and strategic partnerships position it for cash flow breakeven by 2026. Read here for an analysis ...

We recently published a list of These 10 Stocks Are On Fire Right Now. In this article, we are going to take a look at where ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...